

Intrasense initiates the phase-out (“End of Life”) of Myrian®, Liflow®, DUOnco™ Liver and DUOnco™ Bone, and launches a new workforce adjustment plan

- **A deliberate strategic refocusing:** Intrasense is now concentrating all of its resources on **DUOnco™ Pancreas** and **DUOnco™ Unity**, its artificial intelligence solutions dedicated to oncology follow-up.
- **Myrian®** : following the failure of the divestment project announced on August 3, 2026¹, the Company is initiating the phase-out of the marketing and support of the Myrian® solution.
- **Liflow®** : as the detection and tracking algorithmic core of Liflow® is now integrated into DUOnco™ Unity, Intrasense reaffirms its viewer-agnostic positioning by discontinuing the commercialization, which has been in controlled release since Q4 2025.
- **DUOnco™ Liver and DUOnco™ Bone** : the functionalities of these solutions are now integrated within DUOnco™ Unity, which received CE marking on August 21, 2026², making it no longer a priority to maintain them in parallel.
- **A workforce adjustment plan** : in line with this refocusing, a new restructuring plan aimed at adjusting the size of the Company's teams to its new scope of activity will be rolled out by the end of 2026.

Montpellier, France, September 15, 2026, 5:45 p.m. CET. **Intrasense** (ISIN: FR0011179886 – Ticker: ALINS), a **French expert in medical** imaging (“Intrasense” or the “**Company**”), announces the launch of an end-of-life process (“*End of Life*”) for its solutions **Myrian®**, **Liflow®**, **DUOnco™ Liver** and **DUOnco™ Bone**, as well as the launch of a new restructuring plan intended to adjust the size of its teams to its new scope of activity.

Myrian®: drawing the consequences of the uncompleted divestment project

As indicated on August 3, 2026¹, the discussions did not result in an agreement, and the envisaged transaction could not be completed on the terms presented.

In this context, and after reviewing the available options, the Company's Board of Directors decided to initiate an end-of-life process (*End of Life*) for the **Myrian®** solution. This process will be carried out gradually and in a controlled manner, in order to comply with regulatory obligations and ensure continuity of service to existing clients during the transition period.

¹ Press release dated August 3, 2026 – Withdrawal of the project to divest the Myrian® business to EDL

² Press release dated 21 August 2026 – DUOnco™ Unity, first multi-organ AI CE-certified for the follow-up of cancers on CT scans

Liflow®, DUOnco™ Liver, DUOnco™ Bone: functionalities now covered by DUOnco™ Unity

On August 21, 2026², Intrasense announced that it had obtained CE marking for DUOnco™ Unity, the first multi-organ artificial intelligence solution CE-certified (MDR Regulation 2017/745) combining, within a single device, the automated detection, segmentation and longitudinal follow-up of focal lesions across the entire thoraco-abdomino-pelvic (TAP) CT scan — including notably the organs covered by **DUOnco™ Liver** and **DUOnco™ Bone**.

Since its controlled release in Q4 2025, **Liflow®** has been progressively deployed at a limited number of clinical sites, without the usage feedback gathered over this one-year period confirming the expected level of adoption. At the same time, Intrasense's strategy has been refined around the goal of offering a longitudinal oncology follow-up solution that is fully agnostic with respect to the viewers used by its clients. The lesion detection and tracking algorithmic core is now integrated into DUOnco™ Unity, which takes over and extends this capability independently of any proprietary viewer.

As a result, Intrasense is also initiating the phase-out of these three solutions, according to terms and a timetable communicated individually to each client concerned.

A streamlined roadmap centered on DUOnco™ Pancreas and DUOnco™ Unity

This refocusing allows Intrasense to concentrate all of its human, technological and commercial resources on its two flagship solutions: **DUOnco™ Pancreas** and **DUOnco™ Unity**, supporting a “pure player” strategy in artificial intelligence applied to oncology, in line with the strategic plan already under way at the Company.

A new restructuring plan to adjust the size of the teams

In line with this strategic refocusing and building on the cost-savings plan already under way since the second half of 2025³, the Company's Board of Directors has decided to launch a new restructuring plan aimed at adjusting the size of the Company's teams to its new scope of activity, refocused on DUOnco™ Pancreas and DUOnco™ Unity.

The terms of this plan, which will be defined in accordance with the applicable information and consultation procedures with employee representative bodies, are expected to be rolled out by the end of 2026. It forms part of the Company's trajectory toward achieving financial break-even, while ensuring the continuity of ongoing operations and commercial commitments.

Next financial communication:

H1 2026 Results: September 28 (after market close)

³ Press release dated December 18, 2025 – Intrasense confirms its 2025 financial targets and revises its strategic roadmap

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet group since 2023, Intrasense designs medical imaging software solutions, now resolutely focused on artificial intelligence.

Intrasense's product portfolio includes :

- Myrian®, an advanced visualization platform equipped with state-of-the-art clinical tools, which simplifies the interpretation of all types of images.
- DUOnco™, the range of AI algorithms specialized in oncology, notably for the detection of pancreatic lesions and oncology follow-up.
- Liflow®, a solution dedicated to the longitudinal follow-up of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with tools of strong medical value, facilitating the analysis, diagnosis and management of patients.

More information at www.intrasense.fr

Contacts

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay
Tel.: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray
Tel. : +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com